MarketCap
Facebook
X
TelegramQuarterly report 2022-Q2
added 08-09-2022
Tyme Technologies EV/EBITDA Ratio 2011-2026 | TYME
Annual EV/EBITDA Ratio Tyme Technologies
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 3.64 | -6.19 | -4.81 | -9.24 | -16.5 | - | -99.1 | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.64 | -99.1 | -22 |
EV/EBITDA Ratio of other stocks in the Biotechnology industry
| Issuer | EV/EBITDA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
ADMA Biologics
ADMA
|
-4.17 | $ 16.34 | -0.24 % | $ 3.89 B |  USA |
 |
MorphoSys AG
MOR
|
-0.591 | - | 2.43 % | $ 254 M |  Germany |
 |
Axsome Therapeutics
AXSM
|
-8.03 | $ 165.22 | 0.71 % | $ 8.22 B | USA |
 |
Graybug Vision
GRAY
|
-0.336 | - | -11.23 % | $ 9.65 M | USA |
 |
Apellis Pharmaceuticals
APLS
|
-6.39 | $ 19.73 | -2.13 % | $ 2.49 B | USA |
 |
Aptorum Group Limited
APM
|
29.4 | $ 0.8 | 1.02 % | $ 4.36 M |  China |
 |
I-Mab
IMAB
|
595 | - | - | $ 866 M | China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
10.7 | - | - | $ 40.3 B | USA |
 |
Acer Therapeutics
ACER
|
-3.39 | - | 2.71 % | $ 14 M | USA |
 |
Biophytis SA
BPTS
|
-17.6 | - | -13.47 % | $ 169 M |  France |
 |
Ampio Pharmaceuticals
AMPE
|
-20.4 | - | -11.43 % | $ 502 K | USA |
 |
BioLineRx Ltd.
BLRX
|
-53.5 | $ 2.85 | 1.25 % | $ 908 M |  Israel |
 |
AbCellera Biologics
ABCL
|
9.24 | $ 3.71 | -0.13 % | $ 1.11 B |  Canada |
 |
Athersys
ATHX
|
0.437 | - | 3.77 % | $ 22.4 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-3.42 | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
0.796 | - | -18.52 % | $ 27.3 M |  Britain |
 |
AVEO Pharmaceuticals
AVEO
|
-1.76 | - | - | $ 521 M | USA |
 |
BioMarin Pharmaceutical
BMRN
|
671 | $ 59.28 | 1.28 % | $ 11.4 B | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
-5.59 | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
8 | - | -4.8 % | $ 255 M | USA |
 |
Capricor Therapeutics
CAPR
|
-2.14 | $ 26.06 | 0.77 % | $ 698 M | USA |
 |
BridgeBio Pharma
BBIO
|
-4.37 | $ 65.0 | 0.73 % | $ 12.4 B | USA |
 |
Adverum Biotechnologies
ADVM
|
-1.32 | - | - | $ 86.2 M | USA |
 |
CymaBay Therapeutics
CBAY
|
-1.63 K | - | - | $ 3.45 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
14 | - | - | - |  Russia |
 |
Avid Bioservices
CDMO
|
109 | - | - | $ 789 M | USA |
 |
Codexis
CDXS
|
-100 | $ 1.0 | 2.04 % | $ 73.4 M | USA |
 |
Certara
CERT
|
256 | $ 7.43 | 2.56 % | $ 1.19 B | USA |
 |
ARCA biopharma
ABIO
|
1.84 | - | 1052.0 % | $ 415 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
-0.833 | - | - | $ 169 M | USA |
 |
Caladrius Biosciences
CLBS
|
0.677 | - | -16.75 % | $ 25.8 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-5.5 | - | - | $ 2.17 B | USA |
 |
Clovis Oncology
CLVS
|
-3.86 | - | -7.23 % | $ 13 M | USA |
 |
Acorda Therapeutics
ACOR
|
0.777 | - | -24.86 % | $ 820 K | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
-0.0315 | - | - | $ 231 M | USA |
 |
Coherus BioSciences
CHRS
|
-4.11 | $ 1.77 | 7.27 % | $ 167 M | USA |
 |
Acasti Pharma
ACST
|
1.8 | - | 4.01 % | $ 150 M | Canada |
 |
CTI BioPharma Corp.
CTIC
|
-0.985 | - | - | $ 1.2 B | USA |
 |
CohBar
CWBR
|
0.216 | - | -15.44 % | $ 2.2 M | USA |
 |
Cyclacel Pharmaceuticals
CYCC
|
0.195 | - | -5.98 % | $ 34.1 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
-0.975 | - | -4.36 % | $ 27 M | USA |
 |
Cabaletta Bio
CABA
|
0.778 | $ 3.36 | 3.23 % | $ 3.92 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
-1.5 | - | - | $ 2.18 B | USA |
 |
CureVac N.V.
CVAC
|
-7.74 | - | - | $ 867 M | Germany |
 |
Aeterna Zentaris
AEZS
|
4.4 | - | 5.93 % | $ 314 M | Canada |
 |
CorMedix
CRMD
|
-3.52 | $ 7.09 | 2.53 % | $ 361 M | USA |
 |
Corvus Pharmaceuticals
CRVS
|
0.244 | $ 17.3 | -1.31 % | $ 831 M | USA |
 |
AgeX Therapeutics
AGE
|
-1.85 | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-4.27 | - | - | $ 1.01 B | USA |